Literature DB >> 33503295

Comprehensive pathological assessment of histological subtypes, molecular subtypes based on immunohistochemistry, and tumor-associated immune cell status in muscle-invasive bladder cancer.

Junichi Ikeda1,2, Chisato Ohe1, Takashi Yoshida2, Naoto Kuroda3, Ryoichi Saito2, Hidefumi Kinoshita2, Koji Tsuta1, Tadashi Matsuda2.   

Abstract

Molecular assessments of muscle-invasive bladder cancer (MIBC) have yielded several molecular categorizations associated with basal and luminal subtypes or tumor-associated immune cell status (TAICs). However, the histological relationships among histological subtypes, molecular subtypes, and TAICs and their clinical implications remain unclear. Thus, we aimed to evaluate the histological associations among these factors and their clinicopathological outcomes. We retrospectively analyzed 106 patients with MIBC who underwent radical cystectomy. The histological subtypes and TAICs were evaluated with hematoxylin and eosin staining, while the basal and luminal molecular subtypes were determined by immunohistochemical expression of cytokeratin (CK) 5/6, CK14, CK20, GATA3 and uroplakin II. Urothelial carcinoma with squamous differentiation and the sarcomatoid variant were highly associated with the basal subtype (P < 0.001 and P = 0.04, respectively). Additionally, high TAICs were significantly correlated with the basal subtype (P < 0.001). Although there was no significant difference in the cancer-specific survival (CSS) rate between molecular subtypes (P = 0.295), TAICs significantly discriminated CSS rates (P < 0.001). Furthermore, the combination of molecular subtypes and TAICs significantly stratified cancer-specific mortality rates. In conclusion, a comprehensive pathological evaluation of histological subtypes, molecular subtypes, and TAICs is feasible and can influence the oncological outcome.
© 2021 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  bladder cancer; immunohistochemistry; molecular subtype; tumor-associated immune cells; urothelial carcinoma

Year:  2021        PMID: 33503295     DOI: 10.1111/pin.13060

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  5 in total

1.  CD155 immunohistochemical expression in upper tract urothelial carcinoma predicts poor prognosis.

Authors:  Junichi Ikeda; Chisato Ohe; Takashi Yoshida; Ryoichi Saito; Koji Tsuta; Hidefumi Kinoshita
Journal:  Oncol Lett       Date:  2022-09-28       Impact factor: 3.111

2.  Histologic-Based Tumor-Associated Immune Cells Status in Clear Cell Renal Cell Carcinoma Correlates with Gene Signatures Related to Cancer Immunity and Clinical Outcomes.

Authors:  Chisato Ohe; Takashi Yoshida; Junichi Ikeda; Toyonori Tsuzuki; Riuko Ohashi; Haruyuki Ohsugi; Naho Atsumi; Ryosuke Yamaka; Ryoichi Saito; Yoshiki Yasukochi; Koichiro Higasa; Hidefumi Kinoshita; Koji Tsuta
Journal:  Biomedicines       Date:  2022-01-29

3.  Prognostic impact of stromal periostin expression in upper urinary tract urothelial carcinoma.

Authors:  Kosuke Miyai; Kazuki Kawamura; Keiichi Ito; Susumu Matsukuma; Hitoshi Tsuda
Journal:  BMC Cancer       Date:  2022-07-18       Impact factor: 4.638

Review 4.  Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation.

Authors:  Francesca Sanguedolce; Magda Zanelli; Andrea Palicelli; Stefano Ascani; Maurizio Zizzo; Giorgia Cocco; Lars Björnebo; Anna Lantz; Matteo Landriscina; Vincenza Conteduca; Ugo Giovanni Falagario; Luigi Cormio; Giuseppe Carrieri
Journal:  Int J Mol Sci       Date:  2022-07-16       Impact factor: 6.208

Review 5.  Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression.

Authors:  Francesca Sanguedolce; Magda Zanelli; Andrea Palicelli; Stefano Ascani; Maurizio Zizzo; Giorgia Cocco; Lars Björnebo; Anna Lantz; Ugo Giovanni Falagario; Luigi Cormio; Giuseppe Carrieri
Journal:  Int J Mol Sci       Date:  2022-07-15       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.